RxDoctor Payments Data

David Goldberg, MD

Ophthalmology · Wyomissing, PANPI 1578543781

Payments from drug & device makers

$4,943in general payments, 2019–2025

Across 75 payments — averaging $65.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • Regeneron Healthcare Solutions, Inc.$104
  • Alcon$94
  • Bausch & Lomb Americas Inc.$54
  • Astellas Pharma US Inc$54
  • Merz Pharmaceuticals, LLC$43
  • plus $280 from 15 others

What the payments were for

  • Speaking & faculty fees$3,68875%
  • Food & beverage$1,25525%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,943 in reported general payments places this provider in the 75th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$230,759
Medicare patients
691
Services billed
4,711

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine28$30,585
TyrvayaVarenicline Tartrate19$12,361
Azelastine Hcl99$3,122
LumiganBimatoprost12$2,825
Fluorometholone42$2,286
Pyridostigmine Bromide44$2,228
Cevimeline Hcl13$2,149
ErythromycinErythromycin Base211$1,995
Tobramycin-DexamethasoneTobramycin/Dexamethasone39$1,496
Timolol Maleate28$1,190
Prednisolone Acetate28$937
Doxycycline Monohydrate12$765
Ofloxacin59$555
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha44$458
Latanoprost30$437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$23$33,41040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Wyomissing

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →